• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Post Menopausal Osteoporosis - Pipeline Review, H1 2012 Product Image

Post Menopausal Osteoporosis - Pipeline Review, H1 2012

  • Published: April 2012
  • 87 pages
  • Global Markets Direct

Post Menopausal Osteoporosis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2012', provides an overview of the Post Menopausal Osteoporosis therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. 'Post Menopausal Osteoporosis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Post Menopausal Osteoporosis.
- A review of the Post Menopausal READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post Menopausal Osteoporosis Overview
Therapeutics Development
An Overview of Pipeline Products for Post Menopausal Osteoporosis
Post Menopausal Osteoporosis Therapeutics under Development by Companies
Post Menopausal Osteoporosis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Post Menopausal Osteoporosis Therapeutics – Products under Development by Companies
Post Menopausal Osteoporosis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Post Menopausal Osteoporosis Therapeutics Development
Amgen Inc.
Merck & Co., Inc.
Ablynx
Pfizer Inc.
Zosano Pharma, Inc.
Osteologix, Inc.
Unigene Laboratories, Inc.
Acceleron Pharma, Inc.
EffRx, Inc.
Radius Health, Inc.
Post Menopausal Osteoporosis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMG 785 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Odanacatib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sotatercept - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Steovess - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NB S101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH Analogs - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OSTORA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aprela - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ALX-0141 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Parathyroid Hormone-Related Protein (1-36) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fablyn - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Denosumab + Teriparatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZP-PTH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zosano PTH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bonviva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actonel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fosamax - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BA058 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 + Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PTH 1-34 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates
Post Menopausal Osteoporosis Therapeutics – Discontinued Products
Post Menopausal Osteoporosis Therapeutics - Dormant Products
Post Menopausal Osteoporosis – Product Development Milestones
Featured News & Press Releases
Apr 04, 2012: UCB And Amgen Initiate Sclerostin Antibody Phase III Program In Patients With Postmenopausal Osteoporosis
Mar 21, 2012: Tarsa Therapeutics Signs Commercial Supply Agreement For Ostora Oral Calcitonin Product With QS Pharma
Feb 29, 2012: Amgen's Prolia To Be Made Available To Patients In Ontario Through Public Drug Plan
Feb 27, 2012: Merck Issues Statement On FOSAMAX Product Liability Trial In New Jersey
Dec 20, 2011: Takeda Announces Acceptance Of Steovess For National Approvals In EU
Dec 13, 2011: Tarsa Therapeutics Targets 2012 NDA Submission For OSTORA Oral Calcitonin
Nov 09, 2011: Unigene Laboratories Announces Positive Top-Line Results Of Phase II Oral PTH Study For Treatment Of Osteoporosis In Postmenopausal Women
Nov 05, 2011: Amgen Announces Positive Data From Open-Label Extension Study Of Prolia
Oct 20, 2011: Unigene Laboratories Completes All Patient Dosing In Phase II Study Of Oral PTH For Treatment Of Osteoporosis In Postmenopausal Women
Oct 03, 2011: Merck Wins Another Federal Bellwether Trial Regarding FOSAMAX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Post Menopausal Osteoporosis, H1 2012
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Amgen Inc., H1 2012
Merck & Co., Inc., H1 2012
Ablynx, H1 2012
Pfizer Inc., H1 2012
Zosano Pharma, Inc., H1 2012
Osteologix, Inc., H1 2012
Unigene Laboratories, Inc., H1 2012
Acceleron Pharma, Inc., H1 2012
EffRx, Inc., H1 2012
Radius Health, Inc., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Post Menopausal Osteoporosis Therapeutics – Drug Profile Updates
Post Menopausal Osteoporosis Therapeutics – Discontinued Products
Post Menopausal Osteoporosis Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Post Menopausal Osteoporosis, H1 2012
Products under Development for Post Menopausal Osteoporosis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos